No evidence on Omicron transmissibility, immune evasion yet: INSACOG

There is no clear evidence regarding transmissibility, immune evasion, or severity of Omicron in India, at this time, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) has said.

Mumbai, coronavirus, tests, covid
IANS New Delhi
2 min read Last Updated : Dec 21 2021 | 7:18 PM IST

There is no clear evidence regarding transmissibility, immune evasion, or severity of Omicron in India, at this time, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) has said.

Underlining that Delta continues to be main variant of concern globally, it said that data is still insufficient to conclude whether the Omicron variant causes mild infection.

"While Delta, including B.1.617.2 (AY) and AY.x sublineages, continues to be the main VOC globally, the Omicron VOC continues to grow rapidly. Cases have continued to increase in South Africa, with smaller but clear rise in hospitalisations," the INSACOG said in the recent weekly bulletin.

The INSACOG said that while there are some indicators that the disease may be milder with Omicron, there is insufficient data to determine whether this is because of prior infections or vaccination. "There is insufficient data for Omicron severity in unvaccinated or partially vaccinated older subjects," it added.

The INSACOG reports genomic surveillance of SARS CoV-2 across the country through sequencing of samples from 'sentinel sites' and also a detailed statewise district analysis for some states.

Meanwhile, the Omicron infection tally has climbed at 200 across the nation as per the Health Ministry report on Tuesday morning. However, out of the total, 77 have been discharged. So far total 12 states have reported the Omicron infection, it said.

--IANS

avr/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus

First Published: Dec 21 2021 | 7:18 PM IST

Next Story